艾欧凡斯生物治疗

最新新闻

• 评级变动
  Goldman Sachs Maintains Iovance Biotherapeutics(IOVA.US) With Sell Rating, Raises Target Price to $2
  \u5e02\u573a\u8d44\u8baf · 2026/2/5
• 评级变动
  H.C. Wainwright Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $9
  \u5e02\u573a\u8d44\u8baf · 2026/6/4
• 评级变动
  Wells Fargo Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $14
  \u5e02\u573a\u8d44\u8baf · 2026/2/26
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Actuate Therapeutics, Inc. (ACTU), Iovance Biotherapeutics (IOVA) and Otsuka Holdings Co (OtherOTSKF)
  TipRanks · 2026/4/22
• 评级变动
  Baird Downgrades Iovance Biotherapeutics(IOVA.US) to Hold Rating, Cuts Target Price to $4
  \u5e02\u573a\u8d44\u8baf · 2026/2/25
• 评级变动
  Analysts' Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (IOVA), Erasca (ERAS) and Tempus AI, Inc. Class A (TEM)
  TipRanks · 2026/2/25
• 评级变动
  Chardan Capital Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $16
  \u5e02\u573a\u8d44\u8baf · 2026/4/11
• 评级变动
  Truist Financial Maintains Iovance Biotherapeutics(IOVA.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/2/25
• 评级变动
  TD Cowen Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $5
  \u5e02\u573a\u8d44\u8baf · 2026/1/29
• 评级变动
  Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/2/4
• 评级变动
  A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $5 to $14
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $5 to $11
  \u5e02\u573a\u8d44\u8baf · 2026/2/25
• Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $15
  \u5e02\u573a\u8d44\u8baf · 2026/9/17
• TD Cowen Initiates Iovance Biotherapeutics(IOVA.US) With Buy Rating, Announces Target Price $10
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• Citizens JMP Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $8
  \u5e02\u573a\u8d44\u8baf · 2026/8/8
• A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $15 to $20
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  Barclays Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Maintains Target Price $11
  \u5e02\u573a\u8d44\u8baf · 2026/7/20
• 评级变动
  Mizuho Securities Maintains Iovance Biotherapeutics(IOVA.US) With Buy Rating, Raises Target Price to $11
  \u5e02\u573a\u8d44\u8baf · 2026/8/18
• Goldman Sachs Upgrades Iovance Biotherapeutics(IOVA.US) to Buy Rating, Raises Target Price to $15
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  A Quick Look at Today's Ratings for Iovance Biotherapeutics(IOVA.US), With a Forecast Between $7 to $13
  \u5e02\u573a\u8d44\u8baf · 2026/8/7

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。